Mukoaktivnye preparaty i obostrenie khronicheskoy obstruktivnoy bolezni legkikh (fokus na karbotsistein)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, increased interest in mucoactive drugs is caused by two reasons: better understanding of the pathophysiology of chronic obstructive pulmonary disease (COPD); in particular, it was found that the lungs are constantly secrete a variety of oxidants produced endogenously as a result of metabolic reactions, and exogenously in response to aeropollutant exposure, including components of tobacco smoke; and evidence that some of mucoactive drugs (N-acetylcysteine, carbocisteine) have antioxidant properties. In this context, special attention should be paid to carbocisteine (S-carboxymethylcysteine, also available carbocisteine lysine salt - S-carboxymethylcysteine lysinate) - mucoregulatory drug with anti-oxidant and anti-inflammatory properties, which are now widely used in the treatment of patients with COPD. The numerous clinical studies suggest that long-term (6-12-month) use of drug in COPD patients is accompanied by reduction of frequency of disease exacerbations and improvement of quality of life for patients.

Full Text

Restricted Access

About the authors

A. I Sinopal'nikov

References

  1. Knowels MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-77.
  2. Fletcher CM, Jones NL, Burrows B, et al. American emphysema and British bronchitis. A standardized comparative study. Am Rev Respire Dis 1964;90:1-13.
  3. Barnes PJ. Chronic obstructive pulmonary disease. Overview. In: Encyclopedia of Respiratory Medicine. Eds. - GJ Laurent, SD Shapiro (eds.). Oxford, UK: Elsevier Ltd. 1st ed. 2006; 1:429-39.
  4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
  5. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit care Med 2008;177:164-69.
  6. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J respire of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
  7. Nannini L, Cates C, Lasserson T, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Data-base Syst Rev 2007;4.
  8. Rennard S, Carverley PM, Goehringer U, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18.
  9. Calverley PM, Rabe K, Goehringer U, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009;374:685-94.
  10. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009;136:734-43.
  11. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.
  12. Balsamo R, Lanata L, Egan CG. Mucoactive Crit Care Med 2008;177:19-26.
  13. Direct cost to primary care of chronic bronchitis. Analysis of a prospective study. Aten Promaria 2001;27:388-94.
  14. Miravitlles M, Calle M, Soiler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications in guidelines. Arch Bronconeumol 2012;48:86-98.
  15. Wedzicha JA, Hurst JR. Chronic obstructive pulmonary disease. Acute exacerbations. In: Encyclopedia of Respiratory Medicine. Eds. GJ Laurent, SD Shapiro (eds.). Oxford, UK: Elsevier Ltd. 1st ed. 2006;1:439-43.
  16. Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011;8:356-62.
  17. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a oncedaily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317-26.
  18. Tashkin DP, Celli B, Senn S, et al. A 4-year trial drugs. Eur Respir Rev 2010;19:127-33.
  19. de Boer WI, Yao H, Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis 2007;2:205-28.
  20. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Darabase Syst rev 2010;CD001287.
  21. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 2002;11:15-35.
  22. Havez R, Degand P, Roussel P, et al. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poumon Coeur 1970; 26:81-90.
  23. Puchelle E, Girard F, Polu JM, et al. Effect of the mucoregulator S-carboxy-methyl-cysteine in patients with chronic bronchitis. Eur J Clin Pharmacol 1978;14:177-84.
  24. Colombo B, Turconi P, Daffonchio L, et al. Stimulation of Cl- secretion by the mucoactive drug S-carboxy-methylcysteinelysine salt in the isolated rabbit trachea. Eur Respir J 1994;7:1622-28.
  25. Asti C, Melillo G, Caselli GF, et al. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol Res 1995;31:387-92.
  26. Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol 2004; 505:169-75.
  27. Yasuda H, Yamaya M, Sazaki T, et al. Carbocysteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J 2006;28:51-58.
  28. Suer E, Sayrac S, Sarinay E, et al. Variation in attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother 2008;14:333-36.
  29. Guizzardi F, Rodighiero S, Binelli A, et al. S-CMC-Lys-dependent stimulation of electrogenic glutathione secretion by human respiratory epithelium. J Mol Med 2006;84:97-107.
  30. Garavaglia ML, Bononi E, Dossena S, et al. S-CMC-Lys protective effect on human respiratory cells during oxidative stress. Cell Physiol Biochem 2008;22:455-64.
  31. Zheng JP, Kang J, Huang SG, et al. Effect of carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study. Lancet 2008;371:2013-18.
  32. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996;63:174-80.
  33. Yasuda H, Yamaya M, Sasaki T, et al. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2006;54:378-80.
  34. Maccio A, Madeddu C, Panzone F, et al. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother 2009;10:693-703.
  35. Tatsumi K, Fukuchi Y. Carbocysteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2007;55:1884-86.
  36. Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-74.
  37. Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr 1999;23:1-6.
  38. Woodhead M, Blasi F, Ewig S, and the ERS/ ESCMID Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011;17(6):1-59.
  39. Синопальников А.И., Романовских А.Г. Рекомендации по ведению взрослых пациентов с инфекциями нижних дыхательных путей // Клин. микробиол. антимикроб. химиотер. 2012. № 14(1).С. 4-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies